SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
-10.5%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$313M
AUM Growth
+$313M
(-21%)
Cap. Flow
-$51.2M
Cap. Flow
% of AUM
-16.34%
Top 10 Holdings %
Top 10 Hldgs %
50.65%
Holding
79
New
24
Increased
12
Reduced
14
Closed
20
Top Buys
| 1 |
Arcellx
ACLX
|
$18M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$13.6M |
| 3 |
Scholar Rock
SRRK
|
$12.9M |
| 4 |
BridgeBio Pharma
BBIO
|
$7.21M |
| 5 |
CG Oncology
CGON
|
$7.1M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$16.2M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$15.7M |
| 3 |
Incyte
INCY
|
$13.4M |
| 4 |
Merus
MRUS
|
$11.3M |
| 5 |
Praxis Precision Medicines
PRAX
|
$10.3M |
Sector Composition
| 1 | Healthcare | 99.51% |
| 2 | Financials | 0.49% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$8.15B
| $26M | 8.29% | 2,578,860 -133,918 | -5% | -$1.35M |
|
|
2
Syndax Pharmaceuticals
SNDX
$1.41B
| $19.6M | 6.26% | 1,598,594 -1,274,007 | -44% | -$15.7M |
|
|
3
Scholar Rock
SRRK
$3.14B
| $18.2M | 5.8% | 566,212 +399,905 | +240% | +$12.9M |
|
|
4
Arcellx
ACLX
$3.85B
| $18M | 5.73% | +273,774 | New | +$18M |
|
|
5
Merus
MRUS
$4.98B
| $14.6M | 4.65% | 346,756 -268,056 | -44% | -$11.3M |
|
6
Immunovant
IMVT
$2.56B
| $14.6M | 4.65% | 853,472 -265,036 | -24% | -$4.53M |
|
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $13.6M | 4.32% | +40,936 | New | +$13.6M |
|
8
Nuvalent
NUVL
$5.52B
| $13.5M | 4.3% | 190,401 +45,167 | +31% | +$3.2M |
|
9
Revolution Medicines
RVMD
$7.1B
| $11.3M | 3.59% | 318,782 +125,247 | +65% | +$4.43M |
|
10
Janux Therapeutics
JANX
$1.37B
| $9.24M | 2.94% | 342,062 +196,186 | +134% | +$5.3M |
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $9.21M | 2.94% | 274,633 -101,212 | -27% | -$3.4M |
|
12
Denali Therapeutics
DNLI
$2.23B
| $9.07M | 2.89% | 667,078 +82,750 | +14% | +$1.12M |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $8.53M | 2.72% | 593,335 -48,629 | -8% | -$699K |
|
14
uniQure
QURE
$896M
| $7.75M | 2.47% | 731,039 +641,039 | +712% | +$6.8M |
|
|
15
BridgeBio Pharma
BBIO
$9.89B
| $7.21M | 2.3% | +208,437 | New | +$7.21M |
|
|
16
CG Oncology
CGON
$2.04B
| $7.1M | 2.26% | +289,823 | New | +$7.1M |
|
|
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
| $7.03M | 2.24% | +159,305 | New | +$7.03M |
|
18
Arcutis Biotherapeutics
ARQT
$1.86B
| $6.88M | 2.19% | 440,073 -60,893 | -12% | -$952K |
|
19
Insmed
INSM
$28.8B
| $6.64M | 2.12% | 87,059 -19,551 | -18% | -$1.49M |
|
20
Alkermes
ALKS
$4.78B
| $6.35M | 2.02% | 192,352 -224,616 | -54% | -$7.42M |
|
21
Akero Therapeutics
AKRO
$3.74B
| $6.32M | 2.02% | +156,185 | New | +$6.32M |
|
22
Biohaven
BHVN
$1.63B
| $6.02M | 1.92% | 250,564 +64,151 | +34% | +$1.54M |
|
23
Cytokinetics
CYTK
$4.23B
| $6.01M | 1.92% | 149,648 +66,072 | +79% | +$2.66M |
|
|
BPMC
24
DELISTED
Blueprint Medicines
BPMC
| $5.48M | 1.75% | +61,927 | New | +$5.48M |
|
25
VistaGen Therapeutics
VTGN
$102M
| $5.11M | 1.63% | 2,366,554 +38,062 | +2% | +$82.2K |
|